Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination

Patja, Annamari; Paunio, Mikko; Kinnunen, Esko; Junttila, Outi; Hovi, Tapani; Peltola, Heikki

doi:10.1067/mpd.2001.111165

Cited by 66 publications

(22 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aseptic meningitis, the Achilles' heel of mumps vaccines (vide infra), has never been documented to be caused by Jeryl Lynn [32] (albeit, in 1 case in Germany, it was claimed to have done so [33,34]). Long-term follow-up studies with Jeryl Lynn-containing MMR vaccine [35][36][37] confirm the general safety of that vaccine.…”

Section: Resultsmentioning

confidence: 88%

Mumps Outbreaks in Canada and the United States: Time for New Thinking on Mumps Vaccines

Peltola

Kulkarni

Kapre

et al. 2007

Clinical Infectious Diseases

133

View full text Add to dashboard Cite

Mumps epidemics in Canada and the United States prompted us to review evidence for the effectiveness of 5 different vaccine strains. Early trials with the Jeryl Lynn vaccine strain demonstrated an efficacy of approximately 95%, but in epidemic conditions, the effectiveness has been as low as 62%; this is still considerably better than the effectiveness of another safe strain, Rubini (which has an effectiveness of close to 0% in epidemic conditions). The Urabe vaccine strain has an effectiveness of 54%-87% but is prone to cause aseptic meningitis. Little epidemiological information is available for other vaccines. The Leningrad-Zagreb vaccine strain, which is widely used in developing countries and costs a fraction of what vaccines cost in the developed world, seems to have encouraging results; in 1 study, the effectiveness of this vaccine exceeded 95%. Aseptic meningitis has also been reported in association with this vaccine, but the benign nature of the associated meningitis was shown recently in Croatia. Also, the Leningrad-3 strain seems to be effective but causes less-benign meningitis. No mumps vaccine equals the best vaccines in quality, but the virtually complete safety of some strains may not offset their low effectiveness. Epidemiological data are pivotal in mumps, because serological testing is subject to many interpretation problems.

show abstract

Section: Resultsmentioning

confidence: 88%

Mumps Outbreaks in Canada and the United States: Time for New Thinking on Mumps Vaccines

Peltola

Kulkarni

Kapre

et al. 2007

Clinical Infectious Diseases

133

View full text Add to dashboard Cite

show abstract

“…Occurrence of GBS following H1N1 influenza vaccination may cause public concern and reluctance to comply with CDC recommendations, which may in turn influence public policy on vaccination, leading to widespread underutilization of vaccines [25,26]. Our results need to be considered in light of the overwhelming benefit of H1N1 vaccinations in reducing viral illness-associated morbidity and mortality [27].…”

Section: Discussionmentioning

confidence: 99%

Guillain-Barré Syndrome after H1N1 Vaccination in the United States: A Report Using the CDC/FDA Vaccine Adverse Event Reporting System (2009)

et al. 2012

View full text Add to dashboard Cite

Background: Although the Guillain-Barré syndrome (GBS) can be associated with the seasonal influenza vaccine, there is no definite evidence that GBS is associated with H1N1 influenza vaccination. The objective of this report is to study the occurrence and characteristics of GBS after H1N1 vaccine administration in the United States in 2009. Methods: Data were acquired from the Vaccine Adverse Event Reporting System and supplemented by additional information obtained from the Center for Biologics Evaluation and Research, under the Federal Freedom of Information Act. Results: A total of 62 individuals (mean age 46.51 ± 22.41 years), 33 of whom were men, developed GBS associated with the H1N1 influenza vaccination in 2009. Sixty GBS cases were reported within 6 weeks after vaccination, with 31 cases (50.0%) reported in the first 2 weeks. The estimated rate of occurrence of GBS was 6.2 cases per 10 million vaccinations, which is comparable to the rate of GBS in the general population. Conclusion: The higher rate of GBS reports in the first 6 weeks after H1N1 vaccination suggests that some GBS cases may be triggered by H1N1 vaccination. This warrants early recognition, treatment, and active surveillance in the postvaccination setting.

show abstract

“…Most of these are case reports or small case series in which the immunisations were linked to GBS by temporal association only, excluding alternative aetiologies or the demonstration of intrathecal antibodies [15,16]. Scientifically speaking, more appropriate case control studies have shown that vaccinations had not been more frequently performed in patients with GBS than in age-and sex-matched control populations [8,17,20,34,43]. An increased incidence of GBS was observed in Finland following a national oral polio vaccination campaign.…”

Section: Discussionmentioning

confidence: 96%

Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study

Scheßl

Luther²,

Kirschner

et al. 2006

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination

Cited by 66 publications

References 36 publications

Mumps Outbreaks in Canada and the United States: Time for New Thinking on Mumps Vaccines

Mumps Outbreaks in Canada and the United States: Time for New Thinking on Mumps Vaccines

Guillain-Barré Syndrome after H1N1 Vaccination in the United States: A Report Using the CDC/FDA Vaccine Adverse Event Reporting System (2009)

Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study

Contact Info

Product

Resources

About